Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - aggregated albumin, quantity: 2.5 mg - injection, powder for - excipient ingredients: stannous chloride dihydrate; sodium chloride; albumin - technetium tc 99m albumin aggregated injection is a lung imaging agent which may be used as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients. technetium tc 99m albumin aggregated injection may be used in adults as an imaging agent to aid in the evaluation of peritoneovenous (leveen) shunt patency.

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - aggregated albumin, quantity: 2.5 mg - injection, powder for - excipient ingredients: sodium chloride; albumin; stannous chloride dihydrate - technetium tc 99m albumin aggregated injection is a lung imaging agent which may be used as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients. technetium tc 99m albumin aggregated injection may be used in adults as an imaging agent to aid in the evaluation of peritoneovenous (leveen) shunt patency.

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: lactose monohydrate; macrogol 6000; hyprolose; macrogol 400; iron oxide red; microcrystalline cellulose; silicon dioxide; purified talc; povidone; hypromellose phthalate; crospovidone; glyceryl monostearate; light magnesium oxide; polysorbate 80; pregelatinised maize starch; methacrylic acid - ethyl acrylate copolymer (1:1); maize starch; sucrose; titanium dioxide; hypromellose; iron oxide yellow - for the symptomatic relief of frequent heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux disease (gord).

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - aggregated albumin, quantity: 2.5 mg - injection, powder for - excipient ingredients: albumin; sodium chloride; stannous chloride dihydrate - technetium tc 99m albumin aggregated injection is a lung imaging agent which may be used as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients. technetium tc 99m albumin aggregated injection may be used in adults as an imaging agent to aid in the evaluation of peritoneovenous (leveen) shunt patency.

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - aggregated albumin, quantity: 2.5 mg - injection, powder for - excipient ingredients: sodium chloride; stannous chloride dihydrate; albumin - technetium tc 99m albumin aggregated injection is a lung imaging agent which may be used as an adjunct in the evaluation of pulmonary perfusion in adults and pediatric patients. technetium tc 99m albumin aggregated injection may be used in adults as an imaging agent to aid in the evaluation of peritoneovenous (leveen) shunt patency.

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: crospovidone; methacrylic acid - ethyl acrylate copolymer (1:1); glyceryl monostearate; hyprolose; lactose monohydrate; macrogol 6000; povidone; purified talc; light magnesium oxide; polysorbate 80; silicon dioxide; pregelatinised maize starch; hypromellose phthalate; iron oxide red; microcrystalline cellulose; macrogol 400; titanium dioxide; hypromellose; maize starch; sucrose - jubium is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - silicon dioxide, quantity: 16 mg; esomeprazole magnesium, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: polysorbate 80; microcrystalline cellulose; pregelatinised maize starch; glyceryl monostearate; macrogol 400; hyprolose; hypromellose phthalate; povidone; crospovidone; lactose monohydrate; iron oxide red; purified talc; methacrylic acid - ethyl acrylate copolymer (1:1); macrogol 6000; light magnesium oxide; titanium dioxide; hypromellose; maize starch; sucrose - jubium is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; hyprolose; polysorbate 80; light magnesium oxide; macrogol 6000; lactose monohydrate; macrogol 400; silicon dioxide; crospovidone; pregelatinised maize starch; iron oxide red; hypromellose phthalate; glyceryl monostearate; methacrylic acid - ethyl acrylate copolymer (1:1); povidone; purified talc; titanium dioxide; hypromellose; maize starch; sucrose - aceomez is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium, quantity: 44.528 mg - tablet, enteric coated - excipient ingredients: pregelatinised maize starch; povidone; macrogol 400; lactose monohydrate; purified talc; light magnesium oxide; polysorbate 80; hypromellose phthalate; silicon dioxide; hyprolose; methacrylic acid - ethyl acrylate copolymer (1:1); microcrystalline cellulose; macrogol 6000; glyceryl monostearate; crospovidone; iron oxide red; titanium dioxide; hypromellose; maize starch; sucrose - esomeprazole jgl is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: povidone; iron oxide red; crospovidone; hypromellose phthalate; hyprolose; lactose monohydrate; macrogol 400; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; microcrystalline cellulose; macrogol 6000; pregelatinised maize starch; glyceryl monostearate; polysorbate 80; light magnesium oxide; silicon dioxide; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - aceomez is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer